Get the Stockscreener App
8.18
7.47%
-0.66
Akari Therapeutics Plc Adr stock is traded at $8.18, with a volume of 21,683.
It is down -7.47% in the last 24 hours and down -19.17% over the past month.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
See More
Previous Close:
$8.84
Open:
$8.72
24h Volume:
21,683
Relative Volume:
0.49
Market Cap:
$18.69M
Revenue:
Net Income/Loss:
$-28.00M
P/E Ratio:
-0.4129
EPS:
-19.8108
Net Cash Flow:
$-10.93M
1W Performance:
-6.73%
1M Performance:
-19.17%
6M Performance:
+59.77%
1Y Performance:
-73.44%
1-Day Range:
$8.025
$8.72
1-Week Range:
$7.00
$9.05
52-Week Range:
$3.015
$33.60
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(929) 274-7510
Address
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
8.18 | 18.69M | 0 | -28.00M | -10.93M | -19.81 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-26 | Upgrade | Maxim Group | Hold → Buy |
| Apr-08-26 | Downgrade | Maxim Group | Buy → Hold |
| Jan-05-26 | Initiated | Ladenburg Thalmann | Buy |
| Jul-18-25 | Initiated | Maxim Group | Buy |
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
Akari Therapeutics plc ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - Sahm
Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101 - Investing.com
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Sahm
Akari Therapeutics Stock Price Forecast. Should You Buy AKTX? - StockInvest.us
Akari Therapeutics Plc Sponsored ADR Revenue Breakdown – LS:A4270Y - TradingView
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - Sahm
Wondering what's happening in today's pre-market session? - ChartMill
Akari Therapeutics partners with Whitehawk on dual payload study By Investing.com - Investing.com South Africa
Akari Therapeutics partners with Whitehawk on dual payload study - Investing.com
Price to earnings forward of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com - Investing.com South Africa
Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com - Investing.com Canada
Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) adds private‑placement warrants and purchase agreement exhibits - Stock Titan
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Finviz
Akari Therapeutics appoints Patricia LoRusso to advisory board - Investing.com
Akari Therapeutics appoints Patricia LoRusso to advisory board By Investing.com - Investing.com India
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Barchart.com
Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each - Stock Titan
Akari Therapeutics completes $8.3m capital raise in Q2 - Investing.com
Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com - Investing.com India
AKTXAkari Therapeutics Plc ADR Options - Finviz
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com South Africa
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com Canada
White Lion resale of 2.5M Akari (NASDAQ: AKTX) ADSs under $25M equity deal - Stock Titan
AKTX Forecast — Price Target — Prediction for 2027 - TradingView
Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX) - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com India
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com South Africa
Akari Therapeutics (AKTX) CEO granted stock options tied to ADS and financings - Stock Titan
Akari Therapeutics (AKTX) interim CFO granted new ADS awards - Stock Titan
A4270Y Forecast — Price Target — Prediction for 2027 - TradingView
AKTX Options Chain — NASDAQ:AKTX - TradingView
Akari Therapeutics PLC (FRA:CLA1) Valuation - GuruFocus
Akari Therapeutics Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 5.7% on Pipeline HopeSurprise Factor Analysis - dars.gov.et
Large share issuance and governance votes ahead at Akari (NASDAQ: AKTX) 2026 AGM - Stock Titan
Diluted earnings per share (diluted EPS) of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
symbol__ Stock Quote Price and Forecast - CNN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Which stocks have an unusual volume on Thursday? - ChartMill
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akari Therapeutics Plc Adr Stock (AKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bazemore Robert B | Director |
Oct 14 '26 |
Option Exercise |
0.00 |
3,866 |
2 |
22,759 |
| Gaslightwala Abizer | CEO |
Oct 14 '26 |
Option Exercise |
0.00 |
27,066 |
11 |
41,173 |
| Patel Samir Rashmikant | Director |
Jul 07 '26 |
Option Exercise |
0.43 |
22,474 |
9,681 |
98,241 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):